This report will discuss the key lectures on head and neck cancer (HNC) presented during the 2014 annual meeting of the European Society for Medical Oncology. After addressing the novelties in immunotherapeutic therapy for HNC, the top stories on news promising drugs will be discussed. In addition some presentations discussing the set up and implementation of practice guidelines in HNC will be addressed to end of with some innovations on biomarkers.
(BELG J MED ONCOL 2014;8(4):180–3)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
